Cargando…

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

BACKGROUND: Interleukin-2 (IL-2) serves as a pioneer of immunotherapeutic agent in cancer treatment. However, there is a considerable proportion of patients who cannot benefit from this therapy due to the limited clinical responses and dose-limiting toxicities. Mounting evidence indicates that comme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Linlin, Sheng, Jianyong, Chen, Guozhong, Zhu, Peng, Shi, Changping, Li, Bei, Park, Chaiwoo, Wang, Jingyi, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542661/ https://www.ncbi.nlm.nih.gov/pubmed/33028692 http://dx.doi.org/10.1136/jitc-2020-000973

Ejemplares similares

Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression
por: Shi, Linlin, et al.
Publicado: (2019)

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells
por: LaPorte, Kathryn M, et al.
Publicado: (2023)

IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Implication of (99m)Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
por: Gao, Yu, et al.
Publicado: (2023)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
por: Lopes, Jared E, et al.
Publicado: (2020)

TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization
por: Gardner, Alycia, et al.
Publicado: (2022)

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
por: Chen, Lujun, et al.
Publicado: (2022)

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
por: Zhang, Cangang, et al.
Publicado: (2021)

Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells
por: Bai, Xiaowu, et al.
Publicado: (2022)

Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity
por: Xi, Qing, et al.
Publicado: (2020)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
por: Efimova, Iuliia, et al.
Publicado: (2020)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021)

Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity
por: Wang, Zining, et al.
Publicado: (2021)

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity
por: Kalim, Khalid W, et al.
Publicado: (2022)

BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity
por: Wu, Bogang, et al.
Publicado: (2023)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

Quantifying the impact of immunotherapy on RNA dynamics in cancer
por: Usaite, Ieva, et al.
Publicado: (2023)

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer
por: Ji, Dengbo, et al.
Publicado: (2020)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
por: Chen, Heyu, et al.
Publicado: (2020)

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
por: Zhao, Songbo, et al.
Publicado: (2021)

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)

YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
por: Chen, Saisai, et al.
Publicado: (2023)

Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype
por: Dong, Hongliang, et al.
Publicado: (2020)

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
por: Hu, Jinyang, et al.
Publicado: (2022)

Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens
por: Jang, Hyun J, et al.
Publicado: (2023)

Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis
por: Zhou, Yu-Fu, et al.
Publicado: (2021)

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion
por: Oldham, Robert J, et al.
Publicado: (2020)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htiu8t7cq3chrpfgqv7g78lmbr